Deregulation of protein and lipid kinase activities leads to a variety of pathologies, ranging
from cancer inflammatory diseases, diabetes, infectious diseases, and cardiovascular …

Protein and lipid kinases fulfill essential roles in many signaling pathways that regulate
normal cell functions. Deregulation of these kinase activities lead to a variety of pathologies …

Protein and lipid kinases are often the master regulators of cell signaling in eukaryotic
systems. The human genome codes for more than 500 of these enzymes and their …

Many human malignancies are associated with aberrant regulation of protein or lipid
kinases due to mutations, chromosomal rearrangements and/or gene amplification. Protein …

Great successes have been achieved in developing small-molecule kinase inhibitors as
anticancer therapeutic agents. However, kinase deregulation plays essential roles not only …

Kinase inhibitor research is a comparatively recent branch of medicinal chemistry and
pharmacology and the first small‐molecule kinase inhibitor, imatinib, was approved for …

Small-molecule inhibitors of protein and lipid kinases have emerged as indispensable tools
for studying signal transduction. Despite the widespread use of these reagents, there is little …

Small-molecule drug discovery for cancer therapy is making extraordinary progress within
the realm of advancing novel oncogenic protein kinase inhibitor lead compounds of …

Protein and lipid kinases play key regulatory roles in a number of biological processes.
Unsurprisingly, activating mutations in kinases have been linked to a number of disorders …

Deregulation of kinase activity has emerged as a major mechanism by which cancer cells
evade normal physiological constraints on growth and survival. To date, 11 kinase inhibitors …